Mindera Health™ announces first patient enrolled in the MATCH Study: a clinical utility evaluation of the impact of Mind.Px™ on response rates of psoriasis patients who are prescribed biologics
Retrieved on:
Thursday, October 21, 2021
MD, Certification, Psoriasis, CA, MBA, FAAD, CLIA, NGS, Algorithm, Health, Patient, Machine learning, MATCH, RNA, PPV, Time, JID, Biomarker, Skin, Comorbidity, PX, GLOBE, DNA sequencing, Italian geographical region, CAP, Physician, ISO, DNA, Pharmaceutical industry, Medical device
MATCH is a 16-week randomized clinical utility evaluation of the pre-treatment impact of Mind.Px on biologic drug response rates in patients suffering from psoriasis.
Key Points:
- MATCH is a 16-week randomized clinical utility evaluation of the pre-treatment impact of Mind.Px on biologic drug response rates in patients suffering from psoriasis.
- According to a recent publication reporting data from the largest independent psoriasis registry (CorEvitas),1 real-world patient response rates to hyper-expensive biologics were observed to be approximately 52%.
- These low response rates often lead to switching of therapies and massive wasted healthcare spending.
- Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera Health scientists to take a genetic and transcriptomic snapshot of the skin.